Drug · CHEMBL58
MITOXANTRONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MITOXANTRONE. Drugs and targets, record CHEMBL58. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL58
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | DNA topoisomerase II alpha inhibitor | INHIBITOR | https://conductscience.org/library/genes/7153 |
Source ChEMBL
Diseases53
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| acute myeloid leukemia | Phase 3 | ClinicalTrials.gov | 97 | 97 | https://conductscience.org/library/drugs?q=MONDO_0018874 |
| prostate cancer | Phase 3 | ClinicalTrials.gov | 24 | 24 | https://conductscience.org/library/drugs?q=MONDO_0008315 |
| non-Hodgkin lymphoma | Phase 3 | ClinicalTrials.gov | 17 | 16 | https://conductscience.org/library/drugs?q=MONDO_0018908 |
| acute lymphoblastic leukemia | Phase 3 | ClinicalTrials.gov | 16 | 16 | https://conductscience.org/library/drugs?q=MONDO_0004967 |
| diffuse large B-cell lymphoma | Phase 3 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0018905 |
| follicular lymphoma | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0018906 |
| myelodysplastic syndrome | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0018881 |
| mature T-cell and NK-cell non-Hodgkin lymphoma | Phase 2 | ClinicalTrials.gov | 8 | 8 | https://conductscience.org/library/drugs?q=MONDO_0000430 |
| breast cancer | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| mantle cell lymphoma | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0018876 |
1 to 10 of 53Source Open Targets
See all 53 diseasesTrials219
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 41 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00004124 | S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer | Phase 3 | 983 | 2018-09-04 | mitoxantrone | Its name | ClinicalTrials.gov |
| NCT02421939 | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Phase 3 | 371 | 2019-10-17 | mitoxantrone | Its name | ClinicalTrials.gov |
| NCT01564784 | A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | Phase 3 | 326 | 2018-01-17 | mitoxantrone | Its name | ClinicalTrials.gov |
| NCT03182244 | A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation | Phase 3 | 276 | 2025-01-14 | mitoxantrone | Its name | ClinicalTrials.gov |
| NCT00136084 | Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia | Phase 3 | 238 | 2010-03-26 | mitoxantrone | Its name | ClinicalTrials.gov |
| NCT00577993 | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | Phase 3 | 210 | 2020-11-16 | mitoxantrone | Its name | ClinicalTrials.gov |
| NCT03504410 | Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML | Phase 3 | 200 | 2022-12-13 | mitoxantrone | Its name | ClinicalTrials.gov |
| NCT00002766 | Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma | Phase 3 | 170 | 2016-02-22 | mitoxantrone | Its name | ClinicalTrials.gov |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 1 | 141 | 2025-06-04 | mitoxantrone | Its name | ClinicalTrials.gov |
| NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | Phase 3 | 140 | 2017-06-01 | mitoxantrone | Its name | ClinicalTrials.gov |
1 to 10 of 219
See all 219 trialsComparisons in its trials26
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I: Bicalutamide + Goserelin vs Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin: deaths from any cause | 85 of 469 | 91 of 460 | 929 | NCT00004124 | Trial comparisons |
| Arm I: Bicalutamide + Goserelin vs Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin: serious adverse events | 3 of 469 | 11 of 460 | 929 | NCT00004124 | Trial comparisons |
| Gilteritinib vs Salvage Chemotherapy: deaths from any cause | 204 of 247 | 96 of 124 | 371 | NCT02421939 | Trial comparisons |
| Gilteritinib vs Salvage Chemotherapy: serious adverse events | 211 of 246 | 34 of 109 | 355 | NCT02421939 | Trial comparisons |
| Inotuzumab Ozogamicin vs Defined Investigator's Choice of Chemotherapy: serious adverse events | 85 of 164 | 72 of 143 | 307 | NCT01564784 | Trial comparisons |
| Gilteritinib vs Salvage Chemotherapy: deaths from any cause | 97 of 137 | 85 of 139 | 276 | NCT03182244 | Trial comparisons |
| Gilteritinib vs Salvage Chemotherapy: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 134 of 134 | 119 of 119 | 253 | NCT03182244 | Trial comparisons |
| Gilteritinib vs Salvage Chemotherapy: serious adverse events | 102 of 134 | 71 of 119 | 253 | NCT03182244 | Trial comparisons |
| Arm 1: (HDAC) vs Arm 2:(LDAC): serious adverse events | 23 of 109 | 19 of 114 | 223 | NCT00136084 | Trial comparisons |
| CPI-613 + HD Cytarabine and Mitoxantrone vs Control (HAM) and Control Sub-groups (MEC and FLAG): Complete Remission (CR) | 20 of 98 | 22 of 102 | 200 | NCT03504410 | Trial comparisons |
1 to 10 of 26
See all 26 comparisons in its trialsPapers from its trials137
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL58
GET https://conductscience.org/api/drugs/v1/CHEMBL58/diseases?page=2